Is Peptide Therapy Legal? FDA Status and What You Need to Know in 2026

The Regulatory Landscape Has Shifted

If you have been researching peptide therapy in 2026, you have probably encountered confusing and sometimes contradictory information about what is legal, what is FDA-approved, and what has changed. The confusion is understandable — the regulatory environment for peptides has undergone significant changes over the past two years, and much of the information online is outdated or inaccurate.

This article provides a factual, current overview of where things stand. We will cover how peptide therapy is regulated, the current status of the most commonly used peptides, what changed in 2024 and 2025, and how to ensure your therapy is legitimate. We are not going to speculate on future regulatory decisions or make claims about what the FDA should or should not do. We are going to tell you what is.

How Peptide Therapy Is Regulated

Understanding peptide regulation requires knowing three distinct categories that peptides can fall into.

FDA-Approved Peptides

These are peptides that have gone through the full FDA approval process — preclinical studies, phased clinical trials, and formal review — for a specific medical indication. When a peptide is FDA-approved, it can be manufactured by pharmaceutical companies and prescribed for its approved use. Physicians can also prescribe it off-label for other conditions, which is a legal and common practice in medicine.

Very few of the peptides used in anti-aging and wellness medicine are FDA-approved. The ones that are tend to be approved for narrow indications that differ from how they are used in optimization-focused practices.

Compounded Peptides

This is the category most relevant to anti-aging medicine. Compounding pharmacies — regulated under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act — can prepare peptides for individual patients based on a physician’s prescription. This is the same legal framework that allows pharmacies to compound bioidentical hormones, custom medication dosages, and other preparations not commercially available in the exact form a patient needs.

503A pharmacies compound medications for individual patients based on a specific prescription from a licensed provider. They operate under state pharmacy board oversight with some federal requirements.

503B outsourcing facilities can produce larger quantities of compounded medications under stricter FDA oversight, including compliance with current good manufacturing practices (cGMP). They provide an additional layer of quality assurance and can distribute to healthcare facilities without patient-specific prescriptions.

Both pathways are legal. Both require that the bulk drug substances used in compounding meet specific criteria. And this is where recent regulatory changes have created uncertainty.

Research-Only Peptides

Peptides sold as “research chemicals” or “for research use only” are not intended for human use and are not regulated as medical products. They are sold without pharmaceutical-grade quality controls, without purity verification standards applicable to human medications, and without medical oversight. Purchasing and self-administering research peptides is not the same as receiving peptide therapy from a licensed provider using a licensed pharmacy. The distinction matters for both safety and legality.

Current Status of Common Peptides

Here is the factual status of the peptides most frequently used in anti-aging and optimization medicine as of early 2026.

Sermorelin

Sermorelin is a growth hormone-releasing hormone (GHRH) analog — a 29-amino-acid peptide that stimulates the pituitary gland to produce and release growth hormone naturally. It was previously FDA-approved as Geref Diagnostic for evaluating pituitary growth hormone secretion. The manufacturer voluntarily discontinued the product for commercial reasons, not safety concerns.

Sermorelin is currently available through compounding pharmacies. Because it was previously FDA-approved and has an established safety profile from clinical use, it occupies a relatively stable regulatory position among compounded peptides. It remains one of the most widely prescribed growth hormone secretagogues in anti-aging medicine.

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protective protein found in human gastric juice. It has demonstrated significant tissue-healing, anti-inflammatory, and organ-protective properties in preclinical research. It is not FDA-approved for any indication.

In 2024, the FDA placed BPC-157 on its category 2 list of bulk drug substances under evaluation for use in compounding. Category 2 means the FDA has identified the substance for review but has not made a final determination. This classification has limited BPC-157’s availability through some compounding pathways, particularly 503B outsourcing facilities. The review is ongoing, and the ultimate outcome remains uncertain.

BPC-157 continues to be available through some 503A compounding pharmacies where it meets the applicable requirements for compounding. However, availability has become less consistent than it was prior to 2024, and patients and providers should verify current access through their pharmacy.

CJC-1295

CJC-1295 is a synthetic GHRH analog that stimulates growth hormone release. It is often used in combination with ipamorelin. CJC-1295 is not FDA-approved. It is available through compounding pharmacies and has not been placed on the FDA’s restricted categories as of this writing, though the broader compounding review process could affect its status.

CJC-1295 exists in two forms: with and without DAC (Drug Affinity Complex). The version without DAC — often called CJC-1295 no DAC or Modified GRF 1-29 — has a shorter half-life and is generally preferred in clinical practice for its more physiologic growth hormone release pattern.

Ipamorelin

Ipamorelin is a growth hormone-releasing peptide (GHRP) that stimulates growth hormone release through a different receptor pathway than CJC-1295. It is frequently combined with CJC-1295 for a synergistic effect. Ipamorelin is not FDA-approved and is available through compounding pharmacies.

Ipamorelin is considered one of the more selective GHRPs, meaning it stimulates growth hormone release with minimal impact on cortisol and prolactin — a favorable profile compared to older growth hormone secretagogues. It remains available through compounding as of early 2026.

Tesamorelin

Tesamorelin (brand name Egrifta) stands apart from the other peptides on this list because it is FDA-approved — specifically for the reduction of excess abdominal fat in HIV-positive patients with lipodystrophy. It is a synthetic GHRH analog that stimulates natural growth hormone production.

Because it is FDA-approved, tesamorelin has a more established regulatory pathway. Physicians can prescribe it off-label for non-HIV patients seeking its growth hormone-stimulating and visceral fat-reducing effects. Off-label prescribing is a standard, legal medical practice. Tesamorelin can also be obtained through compounding pharmacies.

TB-500

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring peptide involved in tissue repair, wound healing, and inflammation modulation. It is not FDA-approved. TB-500 is available through compounding pharmacies, though it has been subject to increasing regulatory scrutiny as part of the broader FDA review of compounded peptides.

TB-500’s regulatory trajectory is worth monitoring. As the FDA continues its evaluation of bulk drug substances used in compounding, peptides like TB-500 that lack prior FDA approval history may face additional hurdles.

What Changed in 2024 and 2025

The most significant regulatory development affecting peptide therapy has been the FDA’s systematic review of bulk drug substances used in compounding. Here is what happened and why it matters.

The FDA Category Review Process

The FDA maintains lists of bulk drug substances that can be used in compounding. As part of an ongoing review, the agency began evaluating substances nominated for inclusion on these lists, categorizing them based on available safety and efficacy data, historical use, and other factors.

Category 1 substances have been evaluated and found acceptable for use in compounding under specified conditions. Category 2 substances are under active review — the FDA has not made a final determination. Category 3 substances have been evaluated and found not to meet the criteria for compounding.

Impact on Peptide Availability

When a substance is placed on category 2, it creates a gray zone. The substance has not been banned, but its regulatory status is uncertain. Some compounding pharmacies — particularly 503B outsourcing facilities that operate under stricter FDA oversight — may stop compounding category 2 substances until the review is complete. Others, particularly 503A pharmacies, may continue compounding based on their interpretation of applicable regulations.

The practical effect has been uneven. Some patients have experienced difficulty obtaining peptides that were previously readily available. Others have found that their pharmacy continues to compound them without interruption. The inconsistency itself is a source of confusion and frustration for both patients and providers.

What This Means for Patients

If you are currently using or considering peptide therapy, the regulatory changes mean two things. First, work with a provider and pharmacy that stay current on regulatory developments and can advise you on what is available through legitimate channels. Second, understand that the landscape may continue to evolve. A peptide that is available today may face new restrictions tomorrow, and planning for alternatives is prudent.

What has not changed is that peptide therapy prescribed by a licensed physician and dispensed by a licensed compounding pharmacy remains legal. The question is which specific peptides remain available through which pathways — and that requires staying informed.

How to Know If Your Peptide Therapy Is Legitimate

The regulatory complexity around peptides makes it even more important to ensure your therapy comes through proper channels. Here is how to evaluate whether a peptide therapy program meets the standard of legitimate medical care.

Your provider is licensed and conducts a proper evaluation. A legitimate provider performs a clinical evaluation before prescribing — medical history, symptom assessment, lab work, and a discussion of goals and risks. If a provider prescribes peptides without examining you or reviewing your labs, that is a red flag. At Rewind, every peptide protocol begins with a comprehensive assessment.

Your peptides come from a licensed pharmacy. This is non-negotiable. Your peptides should be dispensed by a licensed 503A or 503B compounding pharmacy — not a research chemical supplier, overseas vendor, or unregulated online marketplace. Ask your provider where your peptides are sourced. A legitimate clinic will tell you without hesitation.

You receive ongoing monitoring. Your provider should check relevant lab markers periodically — IGF-1 levels for growth hormone secretagogues, inflammatory markers for healing peptides, and general health markers to ensure safety.

Red Flags to Watch For

Be cautious if you encounter any of the following:

• Peptides sold directly to consumers without a prescription
• Providers who prescribe without a clinical evaluation or lab work
• Products labeled “for research use only” being marketed for human use
• Claims that a peptide is “FDA-approved” when it is actually compounded
• No information provided about the source pharmacy
• No follow-up monitoring or lab work after starting therapy

How Rewind Approaches Peptide Therapy

At Rewind Anti-Aging of Miami, every peptide we prescribe comes from a licensed compounding pharmacy that meets applicable quality and regulatory standards. We do not source from research suppliers or unregulated vendors. If a peptide becomes unavailable through legitimate compounding pathways, we inform our patients and discuss alternatives rather than sourcing from questionable channels.

Our providers stay current on regulatory developments and adjust protocols as the landscape evolves — because the goal is always safe, effective care within the bounds of current regulation. Our process page walks you through how we evaluate, prescribe, and monitor every treatment.

Related Articles

• What Is Peptide Therapy? A Complete Guide
• Peptide Therapy Stacks: Combining Peptides for Maximum Results
• Sermorelin Side Effects: What to Expect

References

1. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A and 503B. FDA.gov. Updated 2024.
2. U.S. Food and Drug Administration. Human Drug Compounding: Policy and Guidance. FDA.gov. Updated 2025.
3. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
4. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
5. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.

---

Interested in peptide therapy through a licensed, medically supervised program? Rewind Anti-Aging of Miami offers peptide therapy using only licensed compounding pharmacies with full medical oversight. See how our process works, review patient results, or schedule a consultation →